Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 4/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 6/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660242 | 0.82 | ROCK2 (0.32) | JAK3ALDH1A1JAK2 | |
| SCHEMBL24325943 | 0.79 | JAK3 (0.36) | JAK3GBA1LCKSMN1; SMN2MITF | |
| SCHEMBL29571645 | 0.79 | JAK3 (0.36) | JAK3GBA1LCKSMN1; SMN2MITF | |
| SCHEMBL29600245 | 0.76 | JAK3 (0.35) | JAK3GBA1LCKSMN1; SMN2MITF | |
| SCHEMBL24323944 | 0.76 | JAK3 (0.35) | JAK3GBA1LCKSMN1; SMN2MITF | |
| SCHEMBL24324142 | 0.75 | JAK3 (0.40) | JAK3GBA1LCKSMN1; SMN2MITF | |
| SCHEMBL11462712 | 0.74 | CDK2 (0.44) | CDK2ALDH1A1 | |
| SCHEMBL3506062 | 0.74 | GPR119 (0.47) | — | |
| SCHEMBL1326628 | 0.72 | CCNT1 (0.42) | CDK2 | |
| SCHEMBL24325981 | 0.70 | POLB (0.44) | JAK3GBA1LCKJAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115139-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| CN-102458579-B | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL | 2014-11-05 | — | — | CN | disclosed |
| EP-2442870-B1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8324201-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8318722-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8314088-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-31 | — | — | US | disclosed |
| CN-102458579-A | Pyrazinoazeza derivatives | TAKEDA PHARMACEUTICAL | 2012-05-16 | — | — | CN | disclosed |
| EP-2442870-A1 | PYRAZINOOXAZEPINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-17 | — | — | US | disclosed |
| WO-2010147226-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR5A, HTR2C, HTR2A | JAK3 2063/4885CDK2 1871/4885GBA1 4700/4885 |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | JAK3 1780/4885CDK2 1006/4885GBA1 4460/4885 |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | JAK3 1780/4885CDK2 1006/4885GBA1 4460/4885 |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | JAK3 1780/4885CDK2 1006/4885GBA1 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.